Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ligand Pharmaceuticals Inc.    LGND

LIGAND PHARMACEUTICALS INC. (LGND)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Ligand Pharmaceuticals : , Janssen Enter R&D Deal

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/11/2018 | 11:34pm CEST
   Micah Maidenberg 
 

Subsidiaries of Ligand Pharmaceutical Inc. (LGND) and Johnson & Johnson have entered into a research-and-development agreement focused on a "transgenic chicken platform" aimed at generating and discovering antibodies for humans, according to a securities filing.

Ligand's company Crystal Bioscience Inc., and Janssen Research & Development LLC, which is part of the Janssen Pharmaceutical Cos. of Johnson & Johnson, agreed to work together on Ligand's development of the platform, the filing said.

Under the deal, Ligand will be able to earn milestone payments contingent on various deliverables and will be able to sell the platform to others in the market.

Write to Micah Maidenberg at micah.maidenberg@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 0.63% 142.88 Delayed Quote.0.53%
LIGAND PHARMACEUTICALS INC. 0.80% 259.84 Delayed Quote.88.26%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LIGAND PHARMACEUTICALS INC
09/12LIGAND PHARMACEUTICALS : Fr. Emmanuel Lemelson Responds to SEC Charges
PR
08/29LIGAND PHARMACEUTICALS : to Participate in H.C. Wainwright 20th Annual Global In..
BU
08/20TODAY'S RESEARCH REPORTS ON TRENDING : Ligand Pharmaceuticals and Geron
AC
08/16LIGAND PHARMACEUTICALS : Makes Offer to Acquire Vernalis, a Leader in Structure-..
AQ
08/11LIGAND PHARMACEUTICALS : Vernalis, weakened by FDA rejections, accepts 33M Ligan..
AQ
08/09LIGAND PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Financi..
AQ
08/09LIGAND PHARMACEUTICALS : Makes Offer to Acquire Vernalis, a Leader in Structure-..
BU
08/08LIGAND PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condi..
AQ
08/06LIGAND : 2Q Earnings Snapshot
AQ
08/06LIGAND PHARMACEUTICALS INC : Results of Operations and Financial Condition (form..
AQ
More news
News from SeekingAlpha
09/18Can Biotech Continue This Rally? 
09/15YOUR DAILY PHARMA SCOOP : FibroGen Fast Tracked, Dr. Reddy's Entry, Bristol-Myer.. 
09/12SEC charges Ligand Pharma short seller with "short and distort" scheme 
09/05Small Caps Are Rising, Biotechs Can't Be Far Behind 
08/28BY THE NUMBERS : Growth Leaders With Strong Momentum 
Financials ($)
Sales 2018 237 M
EBIT 2018 173 M
Net income 2018 146 M
Debt 2018 587 M
Yield 2018 -
P/E ratio 2018 42,23
P/E ratio 2019 75,24
EV / Sales 2018 25,5x
EV / Sales 2019 26,8x
Capitalization 5 440 M
Chart LIGAND PHARMACEUTICALS INC.
Duration : Period :
Ligand Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LIGAND PHARMACEUTICALS INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 256 $
Spread / Average Target -0,82%
EPS Revisions
Managers
NameTitle
John L. Higgins Chief Executive Officer & Director
Matthew W. Foehr President & Chief Operating Officer
John W. Kozarich Chairman
Matthew E. Korenberg CFO, Principal Accounting Officer & EVP-Finance
Vincent Antle Senior VP-Technical Operations & Quality Assurance
Sector and Competitors
1st jan.Capitalization (M$)
LIGAND PHARMACEUTICALS INC.88.26%5 440
CELLTRION, INC.--.--%33 313
IQVIA HOLDINGS INC29.90%25 763
LONZA GROUP21.04%24 749
INCYTE CORPORATION-28.99%14 515
SEATTLE GENETICS, INC.44.86%12 545